Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ODS, NCI research grants

This article was originally published in The Tan Sheet

Executive Summary

Applications for R01, R21 grants to conduct "innovative preclinical and clinical research to determine how diet and dietary factors impact DNA methylation and other epigenetic processes involved with cancer prevention" requested by ODS, National Cancer Institute in recent RFA. Collaboration between nutrition and epigenetic/ DNA methylation experts "to study bioactive food components with cancer preventative properties" is encouraged. NCI will fund seven to 10 grants in FY 2004 with a total of $2.5 mil; ODS will offer $800,000 for three or four grants that year. Letters of intent are due by Feb. 18, applications one month later. Under a separate but related RFA, researchers "can extend the goals of active grants to include studies related to the impact of diet and nutrition on epigenetic events"...

You may also be interested in...

Cipla Granted Approval For First US Proventil Rival

Shortly after wrapping up a Phase III trial for its proposed generic Advair Diskus product in the US, Cipla has won FDA approval for the first generic Proventil HFA product, as it continues to build up steam in the US respiratory market.

UK Publishes COVID-19 Self-Test Specifications

The UK's MHRA is looking for manufacturers to submit COVID-19 self-tests that meet minimum and desired criteria for evaluation, after finding its recently purchased 3.5m self-tests failed to meet these standards. Criteria include no requirement for testing knowledge or training or assistance from a healthcare professional in administering or interpreting the results of the test, as well as a 95% accuracy level. 

Henlius Partners With Mabxience On Trastuzumab

Henlius has struck a deal with Mabxience to market its HLX02 trastuzumab biosimilar in Argentina, Uruguay and Paraguay.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts